

# HEALTHCARE MONTHLY

MAY 2019

*Our healthcare team architects market-defining outcomes for some of the most innovative medical device, life science and diagnostics, healthcare services and pharmaceutical companies in the world.*









BioTech / Pharma

Healthcare Services

Life Sciences/Diagnostics


Medical Devices

## HEADLINE TRANSACTIONS


Bio/Pharma	 <p>IFMTRE A subsidiary of IFM THERAPEUTICS</p>	 <p>NOVARTIS</p>	<ul style="list-style-type: none"> <li>Novartis AG (SWX:NOVN) entered into a definitive agreement to acquire IFM Tre from IFM Therapeutics, Inc. for \$310 million and up to \$1.27 billion in milestones</li> <li>IFM Tre is a biopharmaceutical company developing a suite of small-molecule antagonists</li> <li>Novartis AG researches, develops and markets patented prescription medicines and healthcare products worldwide</li> </ul>
	 <p>PARAGON BIOSERVICES</p>	 <p>Catalent</p>	<ul style="list-style-type: none"> <li>Catalent Pharma Solutions, Inc. entered into a definitive agreement to acquire Paragon Bioservices, Inc. from Camden Partners Holdings, NewSpring Capital and others for approximately \$1.2 billion</li> <li>Paragon Bioservices operates as a contract research and manufacturing organization that focuses on the development and manufacture of biopharmaceuticals</li> <li>Catalent Pharma Solutions, Inc. provides development solutions and delivery technologies for drugs, biologics, and consumer health products</li> </ul>
	 <p>ARATANA THERAPEUTICS</p>	 <p>Elanco</p>	<ul style="list-style-type: none"> <li>Elanco Animal Health Inc. (NYSE:ELAN) entered into an agreement to acquire Aratana Therapeutics, Inc. (NasdaqGM:PETX) for approximately \$240 million, a 39.9% premium</li> <li>Aratana Therapeutics, Inc. focuses on the licensing, development, and commercialization of therapeutics for dogs and cats</li> <li>Elanco Animal Health Inc. develops and markets products for companion and food animals</li> <li>Implied Enterprise Value Multiples: 2.7x Revenue, 10.2x EBITDA</li> </ul>
Life Sci.	 <p>cisbio "a partnership of innovation"</p>	 <p>PerkinElmer For the Better</p>	<ul style="list-style-type: none"> <li>PerkinElmer, Inc. (NYSE:PKI) entered into an agreement to acquire Cisbio Bioassays SAS for approximately \$215 million</li> <li>Cisbio Bioassays develops assays and reagents that are used worldwide to help generate effective therapies</li> <li>PerkinElmer provides analytical solutions and diagnostic services worldwide</li> </ul>

# HEALTHCARE GROWTH & VALUATION TRENDS


Enterprise Value / LTM Revenue




Enterprise Value / LTM EBITDA



LTM Revenue Growth




LTM Gross Margin\*



\*EBITDA Margins shown as the gray line.

LTM Stock Price Index



68% BioTech / Pharma    123% Health Services    118% Life Sci / Diagnostics    118% Medical Devices    114% S&P 500 Index

# SELECTED HEALTHCARE TRANSACTIONS

Target	Acquiror	BioTech / Pharma Transaction
Ceclor Medicine Manufacturing Facility in Suzhou, China	Eddingpharm (China) Co., Ltd.	The Ceclor Medicine Facility in Suzhou, China manufactures pharmaceutical products. Transaction Value: \$380 million.
Chemistry Holdings Inc.	CURE Pharmaceutical Holding Corp.	Chemistry Holdings Inc. develops biopolymer delivery systems for products in the nutraceutical and pharmaceutical industries. Transaction Value: \$110 million.
Cyto-Sen Therapeutics, Inc.	Kiadis Pharma N.V.	Cyto-Sen Therapeutics, Inc. develops natural killer cells with its particle-based expansion and activation process to treat cancer. Transaction Value: \$22 million and up to \$55 million in milestones.

Target	Acquiror	Life Sci / Diagnostics Transaction
Substantially All of the Assets and Certain Specified Liabilities of GenePOC Inc.	Meridian Bioscience Canada Inc.	Substantially All of the Assets and Certain Specified Liabilities of GenePOC Inc. comprises the diagnostic instruments business. Transaction Value: \$50 million and up to \$70 million in milestones.
Seramatrix Corporation	Caprion Proteomics, Inc.	Seramatrix Corporation engages in the development of Seromic profiling assays that can enable the early detection of diseases.
Breakthrough Diagnostics, Inc.	Todos Medical Ltd.	Breakthrough Diagnostics, Inc. develops diagnostic blood tests for Alzheimer's disease.

Target	Acquiror	Health Services Transaction
Advanced Medical Personnel Services, Inc.	AMN Healthcare, Inc.	Advanced Medical Personnel Services, Inc. provides occupational, physical, and speech therapy staffing solutions. Transaction Value: \$200 million. Transaction Multiples: 1.7x Revenue, 11.6x EBITDA
PharmaKey, LLC	Whitsell Innovations, Inc.	PharmaKey, LLC operates as a regulatory consulting firm for pharmaceutical drug development.
Symmetry Workforce Solutions	Aya Healthcare, Inc.	Symmetry Workforce Solutions provides staff management and consultancy services to hospitals.

Target	Acquiror	Medical Devices Transaction
NAMIC Fluid Management Portfolio of AngioDynamics, Inc.	Medline Industries, Inc.	NAMIC Fluid Management Portfolio of AngioDynamics, Inc. comprises the business unit which manufactures closed fluid systems, guidewires, disposable transducers and interventional accessories. Transaction Value: \$168 million.
Kyoto Medical Planning Co., Ltd.	The Japan Wool Textile Co., Ltd.	Kyoto Medical Planning Co., Ltd. manufactures and distributes biodegradable stents and other medical equipment.
Orsus Medical Ltd	Afon Technology Limited	Orsus Medical Ltd manufactures and markets wristband sensors to monitor blood glucose levels.

## Selected TM Capital Healthcare Experience

## TM Capital's Healthcare Industry Contacts



**James McLauren**, Managing Director  
 jmclaren@tmcapital.com  
 212.809.1414



**Michael Goldman**, Managing Director  
 mgoldman@tmcapital.com  
 212.809.1419



**Paul Smolevitz**, Managing Director  
 psmolevitz@tmcapital.com  
 212.809.1416